TABRECTA
PeakNDAORALTABLETPriority Review
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TABRECTA (capmatinib) is an oral small-molecule MET inhibitor approved by the FDA for patients with MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC). It represents a precision oncology approach targeting a specific genetic driver in advanced lung cancer. The drug addresses an unmet need in a rare but clinically important patient subset.
$93MPart D
PeakStable
8.7 years to LOETABRECTA is in peak commercial phase with modest but stable utilization; the brand team is likely focused on patient identification and precision oncology market access strategies rather than rapid growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
Started Jun 2023
44 enrolled
Non-Small-Cell Lung Carcinoma
Special Drug Use-results Surveillance of Tabrecta Tablets
Started Nov 2020
109 enrolled
Non-small Cell Lung Cancer
Career Relevance
TABRECTA careers center on precision oncology execution: deep genetic testing partnerships, patient identification programs, and HCP engagement in genomics-driven NSCLC care. Working on this product builds expertise in rare, molecularly-defined oncology markets with high technical depth but smaller team size compared to blockbuster franchises.
Medical Science Liaison
Worked on TABRECTA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.